NeoGenomics, Inc.

Equities

NEO

US64049M2098

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
13.77 USD +0.66% Intraday chart for NeoGenomics, Inc. -5.17% -14.89%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NeoGenomics, Inc. Announces Senior Leadership Promotions CI
NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics CI
Piper Sandler Adjusts Price Target on NeoGenomics to $20 From $18, Maintains Overweight Rating MT
Goldman Sachs Raises Price Target on NeoGenomics to $19 From $17, Maintains Buy Rating MT
Needham Raises NeoGenomics' Price Target to $24 From $21, Keeps Buy Rating MT
Traders Await Fed Minutes, Nvidia Earnings as US Equity Futures Drop Pre-Bell MT
NeoGenomics Swings to Q4 Adjusted Earnings, Revenue Rises; Issues 2024 Guidance MT
Transcript : NeoGenomics, Inc., Q4 2023 Earnings Call, Feb 20, 2024
NeoGenomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (NEO) NEOGENOMICS Reports Q4 EPS $0.03, vs. Street Est of $-0.03 MT
Earnings Flash (NEO) NEOGENOMICS Reports Q4 Revenue $155.6M, vs. Street Est of $152.5M MT
NeoGenomics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024 CI
Transcript : NeoGenomics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 05:15 PM
Neogenomics, Inc. and Concertai, Llc Announce Collaboration to Advance Population-Scale, Definitive Hematological Research & Generative Ai Solutions At Ash 2023 CI
TD Cowen Cuts Price Target on NeoGenomics to $19 From $22, Maintains Outperform Rating MT
BTIG Cuts Price Target on NeoGenomics to $21 From $25, Keeps Buy Rating MT
Sector Update: Health Care Stocks Rise in Late Afternoon MT
Top Midday Decliners MT
NeoGenomics Shares Fall; Company to Appeal Preliminary Injunction in Natera Copyright Battle MT
Sector Update: Health Care Stocks Steady Premarket Thursday MT
NeoGenomics to Appeal Preliminary Injunction in Natera Copyright Battle MT
Sector Update: Health Care Stocks Advance Thursday Afternoon MT
Natera Winning RaDaR Preliminary Injunction Bodes Poorly for NeoGenomics, Needham Says MT
Natera Wins Preliminary Injunction in Copyright Battle Against NeoGenomics MT
Chart NeoGenomics, Inc.
More charts
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
13.68 USD
Average target price
21.1 USD
Spread / Average Target
+54.24%
Consensus
  1. Stock Market
  2. Equities
  3. NEO Stock
  4. News NeoGenomics, Inc.
  5. NeoGenomics : Earnings Flash (NEO) NEOGENOMICS Posts Q4 EPS $0.14, vs. Street Est of $0.06